Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience

Med Clin (Barc). 2020 Nov 13;155(9):410-411. doi: 10.1016/j.medcli.2020.07.001. Epub 2020 Jul 9.
[Article in English, Spanish]
No abstract available

Publication types

  • Case Reports
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Bacterial Infections / epidemiology
  • Betacoronavirus*
  • COVID-19
  • COVID-19 Drug Treatment
  • Combined Modality Therapy
  • Comorbidity
  • Coronavirus Infections / complications
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / therapy
  • Critical Illness / therapy*
  • Cytokine Release Syndrome / drug therapy*
  • Cytokine Release Syndrome / etiology
  • Diabetes Mellitus / epidemiology
  • Female
  • Humans
  • Hypertension / epidemiology
  • Length of Stay / statistics & numerical data
  • Male
  • Methylprednisolone / therapeutic use*
  • Middle Aged
  • Oxygen Inhalation Therapy
  • Pandemics
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / drug therapy*
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / therapy
  • Respiration, Artificial
  • SARS-CoV-2
  • Superinfection / epidemiology
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • tocilizumab
  • Methylprednisolone